This Research Topic is part of a series with:
Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume II
Mutations of the various genes including kinases are the major reasons for the diverse cellular anomalies, leading to the initiation or growth of the cancer. Protein kinases are a large family of enzymes catalyzing the protein phosphorylation which is one of the critical mechanisms for regulating varied cellular events such as proliferation, cell cycle, apoptosis, motility, growth, and differentiation. Kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of their abnormal growth. Small molecules are employed in the cancer treatment as inhibitors for the kinases and sourced from natural, phytochemical, biological and synthetic organic fine chemicals. Kinase inhibitors are currently proposed as treatments for COVID-19 because they can prevent phosphorylation of key proteins involved in the signal transduction that leads to immune activation and inflammation (e.g., the cellular response to proinflammatory cytokines, interleukin-6). Janus kinase inhibitors interfere with phosphorylation of signal transducer and activator of transcription proteins that are involved in vital cellular functions, including signaling, growth, and survival.
The goal of this Research Topic is to cover recent and novel research trends in the field of designing and identifying novel kinase inhibitors for chemotherapy of cancer and the current COVID-19 pandemic. Additionally we aim to investigate the biochemical events associated between the kinase inhibition and concurrent effects on pro-inflammatory cytokinins and immune responses. This Research Topic is intended to become an international platform for researchers to summarize the most recent developments and ideas in the field of therapeutics for the cancer and COVID-19 pandemic. Further, this topic will emphasize on small organic molecules as kinase inhibitors for COVID-19 therapy, besides the current use of them as potential anticancer agents.
We welcome original research articles, reviews, and hypotheses that cover areas including but not limited to:
• In silico design and synthesis of novel small organic molecules as kinase inhibitors in relation to cancer and COVID-19 therapeutics.
• Multiple antigenic peptides (MAP) as kinase inhibitors for COVID-19 therapeutics.
• Biochemical studies co-relating kinase inhibition and immune response towards COVID-19 treatment.
• Studies on current kinase inhibitors with potential for treatment of cancers.
This Research Topic is part of a series with:
Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume II
Mutations of the various genes including kinases are the major reasons for the diverse cellular anomalies, leading to the initiation or growth of the cancer. Protein kinases are a large family of enzymes catalyzing the protein phosphorylation which is one of the critical mechanisms for regulating varied cellular events such as proliferation, cell cycle, apoptosis, motility, growth, and differentiation. Kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of their abnormal growth. Small molecules are employed in the cancer treatment as inhibitors for the kinases and sourced from natural, phytochemical, biological and synthetic organic fine chemicals. Kinase inhibitors are currently proposed as treatments for COVID-19 because they can prevent phosphorylation of key proteins involved in the signal transduction that leads to immune activation and inflammation (e.g., the cellular response to proinflammatory cytokines, interleukin-6). Janus kinase inhibitors interfere with phosphorylation of signal transducer and activator of transcription proteins that are involved in vital cellular functions, including signaling, growth, and survival.
The goal of this Research Topic is to cover recent and novel research trends in the field of designing and identifying novel kinase inhibitors for chemotherapy of cancer and the current COVID-19 pandemic. Additionally we aim to investigate the biochemical events associated between the kinase inhibition and concurrent effects on pro-inflammatory cytokinins and immune responses. This Research Topic is intended to become an international platform for researchers to summarize the most recent developments and ideas in the field of therapeutics for the cancer and COVID-19 pandemic. Further, this topic will emphasize on small organic molecules as kinase inhibitors for COVID-19 therapy, besides the current use of them as potential anticancer agents.
We welcome original research articles, reviews, and hypotheses that cover areas including but not limited to:
• In silico design and synthesis of novel small organic molecules as kinase inhibitors in relation to cancer and COVID-19 therapeutics.
• Multiple antigenic peptides (MAP) as kinase inhibitors for COVID-19 therapeutics.
• Biochemical studies co-relating kinase inhibition and immune response towards COVID-19 treatment.
• Studies on current kinase inhibitors with potential for treatment of cancers.